Targeted therapies have significantly improved outcomes for patients with non-small cell lung cancer (NSCLC) with actionable mutations. However, many tumors inevitably develop drug resistance and ...

The drug is now approved for adjuvant treatment following tumor resection for patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) (tumors ≥ 4 cm or node ...

An isogenic cell line was created to model cancer patients with the echinoderm microtubule-associated protein-like 4 (EML4)-anaplastic lymphoma kinase (ALK) fusion oncogene and tested for its ...

The recommendation is intended for subjects at high risk of recurrence without epidermal growth factor receptor mutations or anaplastic lymphoma kinase rearrangements. Subjects on this regimen in ...

In October, the FDA approved Bristol Myers’ Opdivo for resectable NSCLC and no known epidermal growth factor receptor mutations or anaplastic lymphoma kinase (ALK) rearrangements, for ...

Dr. Dolsten’s accomplishments include the introduction of a new class of oral medications for autoimmune diseases, the development and approval of targeted anaplastic lymphoma kinase (ALK ...

All the latest breaking news on United States. Browse ibtimes archives of photos, videos and articles on United States.

The introduction of Bruton tyrosine kinase (BTK) inhibitors ... with ALK rearrangements defining anaplastic large cell lymphoma. Mutations in RHOA, IDH2, and STAT3/5B influence peripheral T ...